The Current Status of Irinotecan (CPT‐11) in the United States
- 17 December 1996
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 803 (1) , 272-281
- https://doi.org/10.1111/j.1749-6632.1996.tb26397.x
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.Journal of Clinical Oncology, 1996
- Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.Journal of Clinical Oncology, 1996
- Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.Journal of Clinical Oncology, 1995
- Simultaneous Administration of CPT-11 and Fluorouracil: Alteration of the Pharmacokinetics of CPT-11 and SN-38 in Patients With Advanced Colorectal CancerJNCI Journal of the National Cancer Institute, 1994
- Phase I and pharmacokinetic trial of weekly CPT-11.Journal of Clinical Oncology, 1993
- Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.Journal of Clinical Oncology, 1993